Assuntos
Amantadina/uso terapêutico , Doenças dos Gânglios da Base/tratamento farmacológico , Benzotropina/uso terapêutico , Tranquilizantes/efeitos adversos , Tropanos/uso terapêutico , Adulto , Amantadina/efeitos adversos , Doenças dos Gânglios da Base/induzido quimicamente , Benzotropina/efeitos adversos , Ensaios Clínicos como Assunto , Feminino , Humanos , Masculino , Transtornos Mentais/tratamento farmacológico , Pessoa de Meia-IdadeRESUMO
All currently marketed neuroleptics induce extrapyramidal symptoms (EPS). These EPS are a function of biological sensitivity, neuroleptic molecular structure, dose, age, sex, and duration of neuroleptic treatment. Because of their association with EPS, at times irreversible, and their modest efficacy in the non-schizophrenic patients, neuroleptic administration should be limited predominantly to schizophrenic patients. Furthermore EPS should not be used as a guideline for the efficacy of neuroleptics as formerly assumed. For EPS may occur at subtherapeutic doses of neuroleptics and may be absent in patients experiencing clinical response. Neuroleptic dose should be the lowest efficacious dose required to provide symptom remission. In addition, antiparkinsonian (AP) agents should be administered predominently contraactively and not routinely in combination with neuroleptics. With the judicious administration of neuroleptic agents and AP medication, distressing EPS can be prevented or minimized, while providing control of schizophrenic symptoms.
